ZINACEF (cefuroxime sodium) by R-Pharm US is mechanism of action cefuroxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Approved for including pneumonia, caused by streptococcus pneumoniae, haemophilus influenzae (including ampicillin-resistant strains) and 3 more indications. First approved in 1983.
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
ZINACEF (cefuroxime sodium) is a second-generation cephalosporin antibiotic administered intravenously for bacterial infections. It treats pneumonia, respiratory tract infections, and infections caused by Gram-positive and Gram-negative organisms including Streptococcus pneumoniae and ampicillin-resistant Haemophilus influenzae. The drug works by inhibiting bacterial cell wall synthesis and remains active in the presence of some beta-lactamases.
With LOE approaching, the brand team will likely focus on defending market share against generics while managing declining revenue.
Mechanism of Action Cefuroxime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Cefuroxime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria.
Worked on ZINACEF at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moZINACEF offers limited career growth opportunities due to its LOE-approaching status and mature market position. Roles are primarily defensive and focused on volume protection and managed care negotiations rather than innovation or expansion.